2-chloro-N-(3-ethynylphenyl)pyrimidin-4-amine | 1403933-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-N-(3-ethynylphenyl)pyrimidin-4-amine
• CAS: 1403933-74-3
• 化学式: C₁₂H₈ClN₃
• 分子量: 229.669
• InChiKey: ZCUPITPYDOIZLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-羟丙基)吗啉 、 2-chloro-N-(3-ethynylphenyl)pyrimidin-4-amine 在 sodium 作用下， 以 1,4-二氧六环 为溶剂， 反应 7.0h， 以50%的产率得到2-(3-(morpholinyl)propoxy)-4-(3-ethynylphenylamino)pyrimidine
  参考文献：
  名称：

  一类嘧啶衍生物及其制备抗肿瘤药物的应用

  摘要：

  本发明公开了一类嘧啶衍生物及其在制备抗肿瘤药物中的应用，该衍生物的结构通式为：式中R1为4‑甲基哌嗪基、吗啉基中任意一种；m为2～3的整数；R为连在苯环上任一位置的氟、氯、乙炔基、卤代苄氧基、吡啶基甲氧基或三氟甲基苯氧基，n为1～3的整数；X为氧或硫原子。本发明公开的嘧啶衍生物对人皮肤鳞状癌A431细胞、人结肠癌SW480细胞、人非小细胞肺癌A549细胞和人肺癌NCI‑H1975细胞的增殖均具有明显的抑制作用，可用于制备抗肿瘤药物。

  公开号：

  CN112574177B
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 3-氨基苯乙炔 在 N,N-二异丙基乙胺 作用下， 以 异丙醇 为溶剂， 反应 8.5h， 以5%的产率得到2-chloro-N-(3-ethynylphenyl)pyrimidin-4-amine
  参考文献：
  名称：

  ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS

  摘要：

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。

  公开号：

  US20140080848A1

文献信息

• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS
  申请人：National Taiwan University

  公开号：US20140080848A1

  公开（公告）日：2014-03-20

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。
• Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity
  作者：Kuen-Feng Chen、Kuan-Chuan Pao、Jung-Chen Su、Yi-Chieh Chou、Chun-Yu Liu、Hui-Ju Chen、Jui-Wen Huang、InKi Kim、Chung-Wai Shiau

  DOI：10.1016/j.bmc.2012.08.039

  日期：2012.10

  Cancerous inhibitor of PP2A (CIP2A) is a novel human oncoprotein that inhibits PP2A, contributing to tumor aggressiveness in various cancers. Several studies have shown that downregulation of CIP2A by small molecules reduces PP2A-dependent phosphorylation of Akt and induces cell death. Here, a series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma were evaluated. The di-substituted quinazoline and pyrimidine derivatives were more potent inhibitors of cancer-cell proliferation than the mono-substituted derivatives. In particular, compound 1 with chloride at position 2 of quinazoline was as potent as erlotinib in inducing cell death but no inhibition for EGFR activity. Further assays confirmed a correlation between cell death, and CIP2A and Akt inhibition by these derivatives. Among all the derivatives, compounds 19 and 22 showed the most potent antiproliferative activities and the strongest inhibition of CIP2A and p-Akt expression. (C) 2012 Elsevier Ltd. All rights reserved.
• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANCER DRUGS
  申请人：National Yang-Ming University

  公开号：US20150246891A1

  公开（公告）日：2015-09-03

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
• US9394261B2
  申请人：——

  公开号：US9394261B2

  公开（公告）日：2016-07-19
• Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1<i>H</i>)-pyrazole Derivatives as JAKs Inhibitors
  作者：Xuewu Liang、Jie Zang、Mengyuan Zhu、Qianwen Gao、Binghe Wang、Wenfang Xu、Yingjie Zhang

  DOI：10.1021/acsmedchemlett.6b00247

  日期：2016.10.13

  Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer. Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivatives as potent JAKs inhibitors for cancer treatment. Results from in vitro protein kinase inhibition experiments indicated that compounds 3a-f and 11b are potent JAKs inhibitors. For example, the IC50 values of compound 3f against JAK1, JAK2, and JAK3 were 3.4, 2.2, and 3.5 nM, respectively. In cell culture experiments, compound 3f showed potent antiproliferative activity against various cell lines (PC-3, HEL, K562, MCF-7, and MOLT4) at low micromolar levels, while compound 11b showed selective cytotoxicity at submicromolar levels against HEL (IC50: 0.35;, mu M) and K562 (IC50: 0.37 mu M) cell lines. It is worth noting that both 3f and 11b showed more potent antiproliferative activities than the approved JAKs inhibitor Ruxolitinib.